Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% Higher – What’s Next?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares shot up 5.9% during mid-day trading on Tuesday . The stock traded as high as $20.71 and last traded at $20.19. 88,365 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 388,220 shares. The stock had previously closed at $19.07.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ARCT shares. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Stock Performance

The company has a 50 day simple moving average of $17.56 and a 200 day simple moving average of $20.26. The company has a market capitalization of $562.33 million, a PE ratio of -9.35 and a beta of 2.63.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the prior year, the company earned ($0.61) EPS. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current year.

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at $9,037,533.84. This trade represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 15.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its stake in Arcturus Therapeutics by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 119,181 shares of the biotechnology company’s stock worth $2,902,000 after acquiring an additional 3,578 shares in the last quarter. Quest Partners LLC increased its stake in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares during the period. XTX Topco Ltd purchased a new position in Arcturus Therapeutics in the 2nd quarter valued at approximately $596,000. Point72 DIFC Ltd purchased a new position in Arcturus Therapeutics in the 2nd quarter valued at approximately $188,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Arcturus Therapeutics in the second quarter worth $718,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.